| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Our initial objective was the development of a next-line treatment of anti-vascular endothelial growth factor (VEGF) drugs for the treatment of intraocular proliferative diseases including diabetic retinopathy. For this purpose it is necessary to clarify the pathology of these diseases. We observed the retinal blood flow changes against diabetic macular edema in anti-VEGF drugs, subcutaneous steroid injection and surgery, respectively. In addition, changes in blood flow were observed when macular edema associated with central retinal vein occlusion (CRVO), which is also an intraocular proliferative disease, was treated with an anti-VEGF drug.From these results, we tried to elucidate the pathology.
We reported the results at meeting both in Japan and abroad, and reported on the paper about CRVO.
|
